| Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ... JAMA oncology 3 (9), e172411-e172411, 2017 | 938 | 2017 |
| Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, ... Journal of Clinical Oncology 38 (5), 395-405, 2020 | 642 | 2020 |
| Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 579 | 2020 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 549 | 2019 |
| Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology PE Spiess, N Agarwal, R Bangs, SA Boorjian, MK Buyyounouski, ... Journal of the National Comprehensive Cancer Network 15 (10), 1240-1267, 2017 | 263 | 2017 |
| NCCN guidelines insights: bladder cancer, version 5.2018 TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the national comprehensive cancer network 16 (9), 1041-1053, 2018 | 262 | 2018 |
| A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers H Beltran, C Oromendia, DC Danila, B Montgomery, C Hoimes, ... Clinical Cancer Research 25 (1), 43-51, 2019 | 249 | 2019 |
| Targeted nanotechnology for cancer imaging R Toy, L Bauer, C Hoimes, KB Ghaghada, E Karathanasis Advanced drug delivery reviews 76, 79-97, 2014 | 214 | 2014 |
| Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, ... Journal of clinical oncology 41 (1), 22-31, 2023 | 194 | 2023 |
| Characteristics and survival of malignant cardiac tumors: a 40-year analysis of> 500 patients GH Oliveira, SG Al-Kindi, C Hoimes, SJ Park Circulation 132 (25), 2395-2402, 2015 | 170 | 2015 |
| Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial C Le Tourneau, C Hoimes, C Zarwan, DJ Wong, S Bauer, R Claus, ... Journal for immunotherapy of cancer 6, 1-9, 2018 | 166 | 2018 |
| The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles Y Deng, JK Saucier-Sawyer, CJ Hoimes, J Zhang, YE Seo, ... Biomaterials 35 (24), 6595-6602, 2014 | 162 | 2014 |
| Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. JE Rosenberg, TW Flaig, TW Friedlander, MI Milowsky, S Srinivas, ... Journal of Clinical Oncology 38 (6_suppl), 441-441, 2020 | 125 | 2020 |
| Radiomics analysis on FLT-PET/MRI for characterization of early treatment response in renal cell carcinoma: a proof-of-concept study J Antunes, S Viswanath, M Rusu, L Valls, C Hoimes, N Avril, ... Translational oncology 9 (2), 155-162, 2016 | 122 | 2016 |
| NCCN guidelines insights: bladder cancer, version 2.2016 PE Clark, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 14 (10), 1213-1224, 2016 | 120 | 2016 |
| KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). JS De Bono, JCH Goh, K Ojamaa, JM Piulats Rodriguez, CG Drake, ... Journal of Clinical Oncology 36 (15_suppl), 5007-5007, 2018 | 116 | 2018 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 115 | 2021 |
| Novel therapies are changing treatment paradigms in metastatic prostate cancer E Powers, GS Karachaliou, C Kao, MR Harrison, CJ Hoimes, DJ George, ... Journal of hematology & oncology 13, 1-13, 2020 | 112 | 2020 |
| Surface modified poly (β amino ester)-containing nanoparticles for plasmid DNA delivery RJ Fields, CJ Cheng, E Quijano, C Weller, N Kristofik, N Duong, ... Journal of controlled release 164 (1), 41-48, 2012 | 108 | 2012 |
| Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, ... Cancer 124 (10), 2115-2124, 2018 | 101 | 2018 |
Jonathan E. RosenbergMemorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
